As 2020 continues its relentless beatdown of our psyches, it’s never been harder to stay positive. It’s also never been more important to stay positive. In this edition of NeuroBrief, we’ll give you plenty of reasons to do just that—from a new neuro drug that may treat three separate conditions, to a potential new world…
There’s nothing quite like waking up early on a crisp fall morning, sipping on a steaming cup of coffee, and watching the sun start to shine through the turning leaves. Or is there? As it turns out, even this simple pleasure might bring some serious risks for cognitive health. This week, MDLinx highlights the cognitive…
As flu season ramps up, everyone’s keeping their eyes on COVID-19 numbers, especially patients with neurologic disease and the doctors who treat them. Every day our understanding of how the pandemic impacts these patients becomes clearer, and the image is pretty scary—fitting for the Halloween season. This week we offer insights into how the pandemic…
World Alzheimer’s Day arrived last week and brought with it a host of new research into the world’s most common form of dementia. We’re celebrating with an influx of new dementia insights, including the condition’s ancient history, two new cutting-edge biomarkers, and a pandemic-related condition that doubles its risk. Plus, shocking new data on your…
Between a brand new class of drugs, revelations about ties to pregnancy, updates on off-label drug use, and a slew of new data on disease-modifying therapies, it was a fast-paced week in the world of multiple sclerosis. We’ll keep you abreast of the latest breakthroughs, plus many more from across the world of neurology—like new…
